Kornimate/medical-research-clean huggingface dataset:
effect of action observation therapy in comparison to motor relearning program on balance and mobility among subacute stroke patients

Conditions: Subacute Stroke; Cerebral Stroke; Cerebrovascular Stroke; Posture; Functional Performance

Summary: this study is a randomized controlled trial. the purpose of this study is to determine the effect of action observation therapy in comparison to a motor relearning program on balance and mobility among subacute stroke patients.

action observation therapy has proven its positive effects in improving functional performance in stroke patients compared to other neurological and musculoskeletal conditions motor relearning program is also very effective in improving functional performance in stroke patients but previous studies have shown individual effects of aot and mrp but there is no comparison of aot with mrp on balance and mobility. as a result, this study aims to contribute new data to the sparse literature on subacute stroke patients. the research finidings could provide valuable insights into potential benefits, encouraging evidence-based practices.

Eligibility criteria:
inclusion criteria: * both genders, male and female * ischemic stroke patients * age 45 years and above * mmse\>24 * able to stand independently for 1 minute * patient can maintain starting sitting static position for 10 seconds without arm rest exclusion criteria: * any other neurological disorder * orthopedic conditions(fracture) affecting balance and mobility * visual or auditory impairments

Keywords: action observation therapy motor relearning program
effect of vigabatrin in refractory autoimmune encephalitis patients

Conditions: Autoimmune Encephalopathy

Summary: investigation of efficacy of vigabatrin in refractory autoimmune encephalitis patients


Eligibility criteria:
inclusion criteria: * age 18-85 * possible autoimmune encephalitis * patients who have been diagnosed and treated for encephalitis for more than 4 weeks * patients with epilepsy (eeg finding or clinically) exclusion criteria: * septic shock, fever \>38.5 ℃, o2 saturation \ 25, hr \>120 * previously, mrs=3 or mrs\>3 * mmse\<20 * patients who have terminal disease * eye problem * pregnancy
intraoral administration of botox in patients with dentoalveolar neuropathic pain

Conditions: Neuropathic Pain

Summary: onabotulinum toxin type a (bont-a) is a potent neurotoxin that has been reported to have an effect on afferent (sensory) neurons independent of its action on muscle tone and secretory glands at the periphery.in human studies, the use of bont-a has proven to reduce the severity and intensity of attacks in chronic tension type headaches and chronic neck pain. the preempt study concluded that bont-a could be used as a preventive therapy in chronic migraine patients and fda approval was obtained. according to the international association for the study of pain (iasp), bont-a is recommended for the management of peripheral neuropathic pain with subcutaneous administration of 50-200 units (50-200u) to onabotulinum toxin a to the painful neuropathic area every 3 months as a third line of treatment. to our knowledge, there are no clinical trials published investigating the effect of intraoral administration of bont-a in continuous dentoalveolar neuropathic pain. the aim of this pilot study is to investigate the potential therapeutic effect of intraoral administration of bont-a in patients suffering from continuous neuropathic pain. hypothesis: there will be statistically significant differences in reported pain intensity after the intraoral administration of botox® in patients suffering from chronic continuous dentoalveolar neuropathic pain. a single subject experiment will be conducted with 10 patients where 50 u of bont-a will be injected into the painful dentoalveolar area. eligible subjects will complete a pain diary indicating their pain intensity by means of a visual analog scale during one month to establish a baseline. after the first injection, subjects will continue to monitor the vas daily for 3 months and the infiltration will be repeated a second time following the same protocol. patient's response will be monitored with the daily pain diary.


Eligibility criteria:
inclusion criteria: * history of continuous dentoalveolar pain with clinically evident positive (hyperalgesia, allodynia) and/or negative (hypoaesthesia, hypoalgesia) signs of trigeminal nerve dysfunction and where other possible pain sources have been ruled out. * intractable pain to conventional oral and/or topical pharmacotherapy for neuropathic pain according to the recommendations published by neupsig (neuropathic pain special interest group) including anticonvulsants, snris (serotonin and norepinephrine reuptake inhibitors) and/or tricyclic antidepressants. * subject consent to participate in the study. exclusion criteria: * hypersensitive to any onabotulinum toxin preparation or any component in the formulation. * systemic nerve or muscle disorders * bleeding disorders * dysphagia * breathing problems * pregnancy or breastfeeding * previous treatment with botulinum toxin in the last 4 months.
the safety and dose response to single anal doses of nrl001

Conditions: Faecal Incontinence

Summary: single centre dose-finding and proof-of-concept study in healthy volunteers to assess the effects of single doses of nrl001 on the mean anal resting pressure (marp). in addition, the pharmacokinetics of nrl001 and subject safety are also examined.

this is a single centre dose-finding and proof-of-concept study in healthy volunteers to assess the effects of single doses of nrl001 on the mean anal resting pressure (marp). in addition, the pharmacokinetics of nrl001 and subject safety are also examined. the study consists of four parts, which evaluate different nrl001 concentrations and sites of application. treatments consist of a single local application of either 0.3%, 1% or 3% w/w nrl001 gel applied peri-anally, of either 1% or 3% w/w nrl001 gel applied intra-anally, or 1% w/w nrl001 administered rectally. in addition, a 10 mg nrl001-containing suppository applied to the rectum is assessed.

Eligibility criteria:
inclusion criteria: * no previous history of ano-rectal conditions/diseases. * no history of heart disease. * 18 to 75 years of age. * males and females but pre-menopausal females of child bearing potential must be using adequate contraceptive methods and have a negative pregnancy test before the start of the study. exclusion criteria: * use of medication in the last 30 days with vasodilatory activity. * use of any medication in the last 30 days applied to the anus and/or via the rectum (exception: participation in part a, part b or part c of nrl001-01/2002(hv) * regular intake of more than 21 units of alcohol per week. * pregnant females. * breast feeding mothers. * presence of concomitant gastrointestinal diseases or disorders, such as significant abdominal symptoms and haemorrhoids but also any significant organ (e.g. renal, hepatic or cardiac)dysfunction. * volunteers whom the investigator feels would not be compliant with the requirements of the trial.
new protocol in unexplained infertility

Conditions: Unexplained Infertility

Summary: the new protocol antiui provides good results regarding ovulation and pregnancy rates in patients with unexplained infertility

patients with unexplained infertility has normal investigations regarding hormonal, structural data. semen is normal but no pregnancy occurs. before trying icsi, we could help these patients with antiui

Eligibility criteria:
inclusion criteria: * unexplained infertility * duration less than 5 years * good ovarian reserve amh\> 1.1 * normal patent tubes * no previous trials of iui with the same protocol exclusion criteria: * age \> 35 years * duration of infertility\> 5 years * abnormal semen * hypoplastic tubes * prior failed icsi
t regulatory cells in renal cell carcinoma (pilot study)

Conditions: Renal Cell Carcinoma

Summary: to define the frequency of t regulatory cells in peripheral blood of rcc patients before and after nephrectomy. study hypothesis: that nephrectomy results in a normalisation of peripheral blood t regs in early stage rcc, and a lowering of t regs in advanced rcc.

t regulatory cells (t regs) are a recently identified subset of t cells with inhibitory functions on the immune system. in cancer, it has been shown that there is an increased proportion of t regs in several different human malignancy states. t regs are found to be elevated in peripheral blood mononuclear cells, draining lymph nodes and in the primary tumor itself. there has also been correlation between peripheral blood t regs and tumor stage, tumor relapse and survival. it has been proposed that the t regs are activated and expanded by factors produced by the tumor microenvironment. they are thought to play a role in preventing or demising host t-cell responses against cancer, including a suboptimal host responses to vaccine strategies. strategies to reduce t regs in cancer patients are being explored as a novel immunologic anti-cancer approach. renal cell cancer (rcc) is a tumor with well-known immune-mediated phenomena such as spontaneous regression. there is paucity of data on t regs in rcc. we propose to study the frequency of peripheral blood t regs before and after nephrectomy for rcc. we will document the baseline frequency of t regs in rcc and if nephrectomy results in a change in levels. we hypothesize that nephrectomy will lower peripheral t regs to normal levels in early stage rcc, and will reduce peripheral t reg levels in advanced rcc patients. if found to be so, t regs could in future be used as an indicator of disease recurrence in early stage rcc. in advanced rcc, lowering of t reg levels may help explain the previous hypothesis that debulking nephrectomy results in improved anti-tumor immunity, provide rationale for second debulking procedures, and be correlated with subsequent clinical course. the main laboratory technique is flow cytometry. this will be a pilot study with small patient numbers. only blood samples are required.

Eligibility criteria:
inclusion criteria: subjects must meet all of the inclusion criteria to participate in this study: * diagnosed renal cell carcinoma patients for whom nephrectomy is planned or scheduled as treatment. (preoperative histologic diagnosis is not required.) * all stages of disease are eligible. * adult patients above 21. * ability to provide informed consent exclusion criteria: subjects meeting any of the exclusion criteria at baseline will be excluded: * active infection. * immunocompromised or other active immune disorders. * not on any immunomodulating therapy.

Keywords: rcc patients scheduled nephrectomy
infant formula supplemented with a special fat formulation for premature infants following discharge from hospital

Conditions: Premature Infants

Summary: the purpose of this study is to compare the efficacy and nutritional suitability of 2 infant formulas supplemented with different levels of lcpufa, for premature infants following discharge from hospital.


Eligibility criteria:
inclusion criteria: * premature infants of gestational age 32-34 weeks and aga birth weight who are healthy at time of discharge. * whose mothers are unable to breast feed or have chosen not to breast feed, * whose parents have signed the informed consent form. * only the first among twins will be recorded for the study. exclusion criteria: * chromosomal abnormalities or congenital malformation. * metabolic abnormalities. * central nervous system abnormalities. * severe developmental disorders. * gi problems, gi surgery, necrotizing enterocolitis (nec), gastro-esophageal reflux disease (gerd) requiring nutritional intervention. * milk allergy or intolerance. * growth failure. * chronic disease

Keywords: fat formulation
retrograde intrarenal stone surgery - a method of treating the eswl resistant kidney stone

Conditions: Kidney Stone; Ureteroscopy

Summary: is it possible to decrease the intrarenal pressure in the kidney during endoscopic management of kidney stone by topical administration of drugs? in order to secure fewer complications in ureteroscopic operations the pharmacological agent isoproterenol is tested on pigs and human to determine its potential of lowering intrarenal pressure.


Eligibility criteria:
inclusion criteria: * indication for rirs procedure * age \> 18 years * normotensive * capable of understanding information given exclusion criteria: * previous myocardiac infarct * daily use of alpha- og beta- blocking medicine og calcium antagonists * use of nsaid the last 2 days * stone in the ureter * declared * known malignant disease in urinary tract * bladder disease * nephrostomies inserted * jj-catheters inserted * prisoners * pregnant * nursing mothers

Keywords: kidney stone ureteropyeloscopy renal pelvic pressure
vitamin d and calcium supplement attenuate bone loss among hiv- infected patients receiving tenofovir disoproxil fumarate, lamivudine or emtricitabine and efavirenz

Conditions: Bone Density

Summary: the purpose of this study is to determine whether calcium and vitamin d supplement can attenuate bone loss in hiv-infected-patients in thailand who receive tenofovir disoproxil fumarate.

early initiation of antiretroviral therapy (art) has transformed hiv infection into chronic manageable disease. although incidence of aids-related mortality has decreased, it has increased for other co-morbid conditions including decrease bone mass, osteoporosis, fragility fracture. there are multi-factorial that contribute to bone loss in hiv-infected individuals including hiv virus itself that shift bone remodeling pathway toward bone resorption, lifestyle and behavioral factors, co-morbid conditions and art. initiation of art is associated with 2%-6% reduction in bone mineral density during the first 2 years of treatment regardless of art regimens and then stabilization thereafter in the majority of the study. this magnitude of bone loss is similar to postmenopausal women during the first year. tenofovir disoproxil fumarate (tdf) is a nucleotide analogue reverse transcriptase inhibitor, has been associated with greater bone loss than other reverse transcriptase inhibitors, that is recommended as the first line treatment in thailand. nonetheless there is an evidence in western country that calcium and vitamin d supplement can attenuate bone loss in naive hiv-infected individual who start art with tdf. even though many experts recommend to avoid tdf and prefer abacavir, nrtis which affect bone loss less than other nrtis, in high fracture risk patients, more than less hiv-infected-patients can access to abacavir in resource limiting country. this research aims to study bone mineral density (bmd) in hiv infected-patient in thai population who receive tenofovir with calcium and vitamin d supplement.

Eligibility criteria:
inclusion criteria: * hiv-1-infected patients who start 3tc or ftc,tdf and efv within 3 months before enrollment * age 18-50 years exclusion criteria: * crcl \<60ml/min/1.73 m2 ¶- * caco3 supplement \>500 mg/day or vitamin d supplement \>800 iu/day * steroid used (equivalent to prednisolone\> 5 mg/day more than 3 months ) * osteoporosis treatment * serum ca \>10.5 g/dl * history fragility fracture * pregnancy or breastfeeding * secondary amenorrhea * hyperthyroidism * history of kidney stone * current active opportunistic infection
evaluation of stepped care for chronic pain in iraq/afghanistan veterans (escape)

Conditions: Low Back Pain; Pain; Pain, Intractable

Summary: the purpose of this study is to determine if a stepped-care intervention makes pain symptoms better and reduces activity limitations because of pain. our two primary hypotheses are that in oif/oef veterans with chronic pain: 1. stepped care is more effective than usual care in reducing pain-related disability 2. stepped care is more effective than usual care in reducing psychological distress

through the evaluation of stepped care for chronic pain (escape) trial we aim to develop and test a stepped-care intervention to improve functional and work-related outcomes in operation iraqi freedom/operation enduring freedom veterans with chronic musculoskeletal pain. stepped-care involves starting with lower intensity, less costly treatments initially (step 1) and "stepping up" to more intensive, costly, or complex treatments in patients with inadequate response (step 2). the study design will be a randomized controlled trial. the stepped care approach will involve 12 weeks of a pain self-management program in step 1 followed by 12 weeks of brief cognitive behavioral therapy in participants with inadequate improvement in pain-related disability (step 2). patients treated in usual care will be the control group. thus, the primary objective of the escape trial is to conduct a randomized controlled trial to compare the effectiveness of a stepped care intervention vs. usual care in oif/oef veterans with chronic and disabling musculoskeletal pain and evaluate the impact of this intervention on pain-related disability, work function, psychological distress, and secondary outcomes.

Eligibility criteria:
inclusion criteria: * have musculoskeletal pain of the low back, cervical spine, or extremities * have chronic pain (\>3 months duration) * have moderate functional impairment * have access to a working telephone * indianapolis roudebush va medical center patient or walter reed army medical center patient * willing to travel at least once to study site exclusion criteria: * prior back or cervical spine surgery or surgery pending * active psychosis * incompetent for interview * severe impairment of hearing or speech * active suicidal ideation * current alcohol or other substance dependence or abuse

Keywords: analgesia analgesics cognitive behavioral therapy pain self-management stepped care musculoskeletal pain
identifying saliva markers in inflammatory bowel disease

Conditions: Inflammatory Bowel Diseases

Summary: under normal conditions intestinal mucosa presents a baseline "physiological inflammation" caused by a controlled immune response that eliminates offending dietary and microbial antigens. this inflammation disappears once the cause is eradicated. in case of inappropriate immunological response, the inflammation becomes chronic and harmful, resulting in anatomical and functional abnormalities, namely inflammatory bowel disease (ibd). although it is critical for the ibd patients to undergo early diagnosis and management before the development of severe complications, but as ibd has vague and non-pathognomonic clinical features, the clinician is usually mislead into late suspicion and detection of ibd. diagnosis traditionally depended on a combination of pathologic evaluation together with the histological, clinical, radiological, endoscopic, surgical, laboratory (serological) features. recently, serological markers were identified and became of special interest as they do not only detect the occurrence of ibd but also the potential of its development and may be used as prognostic tools. more recently, stool markers were detected and used for diagnosis. up to now, the market is still lacking a definitive, simple and non-invasive diagnostic tool. saliva can present an alternative form of body fluids that simplify diagnostic procedures. our hypothesis is that ibd patients have special salivary biomarkers that may be identified through salivary analysis, where later on a simple non-invasive test can be applied in the form of an easy-to-use kit, being available at the clinician's clinic for the establishment of an immediate and early diagnosis of the destructive inflammatory bowel disease.


Eligibility criteria:
inclusion criteria: * identified with inflammatory bowel disease exclusion criteria: * medically compromised children * congenital syndromes * children on medication chronically or on the day of the examination * children treated with radiotherapy or chemotherapy.
impact of albendazole -ivermectin on wuchereria bancrofti in mali

Conditions: Lymphatic Filariasis

Summary: lymphatic filariasis is a public health problem in mali. the existing data are not up to date and most of them are more than 15 years old. to address this issue in april 2000, the investigators started studies to update the epidemiology of lymphatic filariasis. there is no ongoing lymphatic filariasis control program in 2000 in mali in terms of preventive chemotherapy treatment or vector control. to fill these gaps, this current study aims to assess the impact of albendazole-ivermectin combination treatment on wuchereria bancrofti infection and transmission in 6 rural highly endemic villages of mali.

lymphatic filariasis is a public health problem in mali. the existing data are not up to date and most of them are more than 15 years old. to address this issue in april 2000, the investigators started studies to update the epidemiology of lymphatic filariasis. as a result, in two rural areas (banambani and sirakoro) located at about 25 km north-east bamako, the parasite prevalence using ict cards in august 2000 were 16% (n=150) and 15.0% (n=113) respectively in banambani and sirakoro. there is no ongoing lymphatic filariasis control program in 2000 in mali in terms of preventive chemotherapy treatment or vector control. to fill these gaps, this current study aims to assess the impact of albendazole-ivermectin combination treatment on wuchereria bancrofti infection and transmission in 6 rural highly endemic villages of mali. the study will be conducted in three phases: the pre treatment assessment of lymphatic filariasis infection and transmission parameters, treatment phase with annual single dose of albendazole and ivermectin and the post treatment assessment of anopheles gambiae s.l mosquitoes, the transmission parameters of the vectors in the community, human infection prevalence post treatment using giemsa -stained thick smears and others test like the immuno chromatographic test (ict).

Eligibility criteria:
inclusion criteria: * resident of the 6 villages * 5 years and above exclusion criteria: * pregnant women * breastfeeding women

Keywords: wuchereria bancrofti anopheles albendazole ivermectin mda
insomnia behavioral intervention study

Conditions: Chronic Insomnia

Summary: this randomized pilot study (n=20) explores the effects of a behavioral intervention, that includes sleep hygiene improvements, in long-term users of sleeping pills, aiming to alleviate or stabilize symptoms of insomnia, monitor and decrease sleeping pill usage. adherence will be monitored by an optional smartphone application.

this randomized pilot study has a goal of enrolling 20 study participants. the investigators will examine the effects of a behavioral intervention, that includes sleep hygiene improvements such as regular sleep schedules, with assisted coaching support from the research team. study participants are long-term users of sleeping pills. the goal is to improve or stabilizie insomnia symptoms and decrease sleeping pill usage. study participant adherence will be monitored by an optional smartphone application.

Eligibility criteria:
inclusion criteria: * age of 55-85 * use of sleeping pill medication for sleep at least 3 nights a week * diagnosed with chronic insomnia by a physician * speaks english above a 6th-grade level * has access to a smartphone and/or smart tablet and can use it * has regular access to internet exclusion criteria: * presence of major depression or other severe psychopathology (e.g., bipolar disorder, psychosis, alcohol/substance abuse, etc.) * presence of an acute or severe medical condition which, in the opinion of the research team, would interfere with the study participant's ability to participate in the research study, such as an acute heart attack, recent severe trauma, etc.